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Abstract
Background: To estimate the radiobiological parameters of three popular normal tissue complication probability
(NTCP) models, which describe the dose-response relations of bladder regarding different acute urinary symptoms
during post-prostatectomy radiotherapy (RT). To evaluate the goodness-of-fit and the correlation of those models
with those symptoms.
Methods: Ninety-three consecutive patients treated from 2010 to 2015 with post-prostatectomy image-guided
intensity modulated radiotherapy (IMRT) were included in this study. Patient-reported urinary symptoms were
collected pre-RT and weekly during treatment using the validated Prostate Cancer Symptom Indices (PCSI). The
assessed symptoms were flow, dysuria, urgency, incontinence, frequency and nocturia using a Likert scale of 1 to 4
or 5. For this analysis, an increase by ≥2 levels in a symptom at any time during treatment compared to baseline
was considered clinically significant. The dose volume histograms of the bladder were calculated. The Lyman-
Kutcher-Burman (LKB), Relative Seriality (RS) and Logit NTCP models were used to fit the clinical data. The fitting of
the different models was assessed through the area under the receiver operating characteristic curve (AUC), Akaike
information criterion (AIC) and Odds Ratio methods.
Results: For the symptoms of urinary urgency, leakage, frequency and nocturia, the derived LKB model parameters
were: 1) D50 = 64.2Gy, m = 0.50, n = 1.0; 2) D50 = 95.0Gy, m = 0.45, n = 0.50; 3) D50 = 83.1Gy, m = 0.56, n = 1.00; and 4)
D50 = 85.4Gy, m = 0.60, n = 1.00, respectively. The AUC values for those symptoms were 0.66, 0.58, 0.64 and 0.64,
respectively. The differences in AIC between the different models were less than 2 and ranged within 0.1 and 1.3.
Conclusions: Different dose metrics were correlated with the symptoms of urgency, incontinence, frequency and
nocturia. The symptoms of urinary flow and dysuria were poorly associated with dose. The values of the parameters
of three NTCP models were determined for bladder regarding four acute urinary symptoms. All the models could fit
the clinical data equally well. The NTCP predictions of urgency showed the best correlation with the patient
reported outcomes.
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Background
The knowledge of dosimetric predictors for acute
genito-urinary (GU) toxicity after intensity modulated
radiotherapy (IMRT) for prostate cancer is largely lack-
ing [1–4]. There is an increasing tendency to pay more
attention to quality of life (QOL) issues, which is espe-
cially relevant in prostate cancer [5]. The incidence of
acute moderate/severe GU toxicities, which play a major
role on QOL, has increased in recent years, due to more
aggressive treatments in terms of prescribed dose and
fractionation schemes [1, 2].
Patient-reported health-related QOL is gaining recogni-
tion as an important outcome measure after cancer treat-
ment [6–8]. The traditional approach in recording normal
tissue toxicity in radiation therapy has been the use of
physician-assessed scoring systems. However, there are mul-
tiple recent reports indicating that this type of assessments
do not agree with patient-based reports and tend to under-
estimate the frequency and severity of treatment-related
symptoms [9, 10]. For example, a recent study analyzed pa-
tients, who received concurrent chemoradiation therapy for
rectal cancer. Although these patients showed the same
grade level of diarrhea as assessed using the Common
Terminology Criteria for Adverse Events (CTCAE), they
had wide variations in their patient-reported diarrhea sever-
ities using a validated QOL instrument [11]. Patient-
reported symptoms after different times post prostate cancer
RT have been recently studied. However, this is not the case
for the symptoms that develop during the course of RT
treatment, involving modern intensity-modulated radiother-
apy (IMRT) with image-guidance.
Modelling the relationship between dosimetric data
and development of acute symptoms during treatment
can ultimately lead to future radiation planning dose
constraints, which may minimize these acute issues,
making radiation treatment even safer and well-tolerated
for patients.
At the department of Radiation Oncology of the Uni-
versity of North Carolina, QOL were prospectively ac-
quired using a validated questionnaire [12] during
weekly treatment visits as part of the routine clinical
work-flow. The purpose of this study is to analyze dose/
volume/outcome data in order to estimate the values of
commonly-used NTCP models and their ability to accur-
ately represent the data.
Methods
Patient data
This retrospective analysis included 93 consecutive pa-
tients, who received post-prostatectomy external beam
radiation therapy (RT) between 2010 and 2015. All the
patients received post-prostatectomy RT with image
guidance using CT on-rails or Tomotherapy cone beam
imaging. All the patients were treated with intensity
modulated radiation therapy (IMRT) or volumetric
modulated arc therapy (VMAT) using 6 MV photons.
The prescribed dose to the planning target volume
(PTV) was 66.6 Gy at 1.8 Gy per fraction delivered in 37
fractions for 7 weeks. Plans were designed to deliver at
least 95% of the prescription dose to the PTV.
Patients completed the Urinary Obstruction/Irritation
scale of the validated Prostate Cancer Symptom Indices
(PCSI) [6, 7] before starting RT (baseline) and weekly
during treatment visits. For this study seven datasets
were available: 1) before or during first week of RT
(93 pt); 2) second week of RT (83 pt); 3) third week of
RT (84 pt); 4) forth week of RT (80 pt); 5) fifth week of
RT (76 pt); 6) sixth week of RT (84 pt); and 7) seventh
or last week of RT (87 pt); The patients that did not
miss more than two visits and were analyzed per symp-
tom were 88 for urine flow, 85 for frequency, 86 for noc-
turia, 88 for dysuria, 90 for urgency and 87 for
incontinence. The symptom questions were rated on a
Likert scale of 1 to 4 or 5, where 1 signified “not at all”
and 4 or 5 signified “frequently or very frequently.” In
this study, a score difference (maximum from all the
weekly recordings) from baseline (score before RT) of
≥2 represented clinical significance [13, 14]. Six urinary
symptoms were examined: 1) Urine flow; 2) Frequency;
3) Nocturia; 4) Dysuria; 5) Urgency; and 6) Incontinence.
Among 93 analyzed patients, 6, 14, 15, 14, 26 and 13
had a ≥ 2 point increase in acute urinary symptoms re-
lated to urine flow, frequency, nocturia, dysuria, urgency
and incontinence, respectively.
We hypothesized that bladder is the organ at risk
where dose received may be associated with develop-
ment of measured acute GU symptoms. Bladder delinea-
tion is part of the standard clinical practice in prostate
cancer radiotherapy. The bladder dose volume histogram
(DVH) was calculated for each patient from their treat-
ment plans. These DVHs were correlated with the
patient reported outcome data of different acute urinary
symptoms. Figure 1 illustrates the distribution of the
DVHs of the patients with and without the symptom of
urgency.
Radiobiological models
The doses in the DVHs were converted to equivalent
doses of 2 Gy per fraction (EDQ2Gy) based on the linear
quadratic model using an α/β value of 3 Gy [15, 16].
EQD2Gy ¼ D 
1þ d
α=β
1þ 2
α=β
0
BB@
1
CCA ð1Þ
where D is the physical dose, d is the dose per fraction.
A dose distribution can be reduced to a single dose
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value using the generalized Equivalent Uniform Dose
(gEUD) concept as follows [17, 18]:
gEUD2Gy ¼
X
i
EQD2Gy
 1=n
i
V i
V tot
 !n
ð2Þ
where Vi is the fractional subvolume of the organ being
irradiated with a given dose and Vtot is the total volume
of the organ. n is a parameter describing the volume de-
pendence of the organ. gEUD2Gy is then used in the LKB
and Logit models as follows [19]:
NTCP ¼ 1ﬃﬃﬃﬃﬃﬃ
2π
p
Zt
−∞
e
−x2
2 dx ð3Þ
where
t ¼ gEUD2Gy−D50
m  D50 ð4Þ
The Logit model is a logistic equation, which produces
an analytical sigmoidal shaped curve commonly used in
biology and it is defined in the following way [20]:
NTCP ¼ 1
1þ D50gEUD2Gy
 k ð5Þ
The Relative Seriality (RS) model used in this work
applies a different approach to account for the vol-
ume dependence and it is mathematically expressed
as follows [21, 22]:
NTCP ¼ 1−
YM
i¼1
1−P Dið Þsð ÞΔvi
" #1=s
ð6Þ
where
P Dið Þ ¼ exp −eeγ− EQD
i
2Gy=D50ð Þ eγ− ln ln2ð Þ
h i
ð7Þ
where P(Di) is the probability of response of an organ
having the reference volume and being irradiated to dose
Di. From the NTCP values the biologically effective uni-
form dose (D) can be derived by the following formula:
P D
! 
≡ P D
 
⇒D ¼
eγ− ln − ln P D
!   
eγ− ln ln2ð Þ ð8Þ
The basic parameters of each model are: D50, which is
the dose for a complication rate of 50%, the slope (gradi-
ent) of the dose response curve (m for LKB, k for Logit
and γ for RS), and the parameter that accounts for the
volume dependence of the organ (n for LKB and Logit, s
for RS).
Statistical methods for fitting the NTCP models and
evaluating the goodness-of-fit
The values of the parameters of the NTCP models and
their 95% confidence intervals were determined using
the maximum likelihood method. In this process, the
predictions of the NTCP models were fitted to the clin-
ical outcome results by changing the values of the model
parameters until best estimates could be reached [23,
24]. The profile likelihood method was used to deter-
mine the confidence intervals of the model parameters.
This method is often used when accurate interval esti-
mates are difficult to obtain using standard methods (for
example, when the log-likelihood function is highly non-
normal in shape). For the 95% confidence region, the al-
lowable difference from the maximum lnLmaxðxiÞ− ln
LmaxðxiÞ is 1/2 × 3.84 = 1.92, for one degree of freedom.
The goodness-of-fit of the different NTCP models was
assessed through the area under the receiver operating
characteristic curve (AUC), maximum of the log-
likelihood function, normal error distribution and
Akaike information criterion (AIC) [25, 26]. More spe-
cifically, the AUC of a receiver operating characteristic
(ROC) curve was computed and compared to the level
of 0.5 (equivalent to a random predictor) [26]. The prob-
ability of achieving a worse fit was assessed by compar-
ing the maximum log-likelihood value against the
average log-likelihood value and its variance assuming a
Gaussian distribution of the log-likelihood function [14,
23]. The Akaike information criterion was used to com-
pare the fitting and complexity of the different models
[25]. A lower Akaike number for a model indicates
Fig. 1 The dose-volume histograms (DVHs) of bladder for the acute
symptom of urinary urgency. The DVHs of the patients with the
symptom are represented by solid lines, whereas those without the
symptoms by dashed lines. The thick lines represent the average
DVHs, whereas the thin lines indicate the 68% confidence interval
(one standard deviation)
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superiority of that model. Finally, the Odds Ratio (OR)
method was applied to identify NTCP thresholds beyond
which the risk of toxicity increases significantly.
Results
Table 1 presents a summary of the average mean doses
to bladder for the patients with and without acute urin-
ary symptoms. Additionally, the average values of the
dose-volume metrics that correlated best with the out-
come date are shown. Urine flow and dysuria were not
included in this table because the correlation between
their dosimetric and outcome data was poor. Conse-
quently, the values of the parameters of the NTCP
models were determined for the symptoms of urgency,
incontinence, frequency and nocturia (Table 2). The cor-
responding dose-response curves for the examined
models and structures are shown in Fig. 2 Broadly,
speaking, the three examined models essentially show
equivalent goodness-of-fit per symptom. The analytical
results are shown in Table 3. For the models and symp-
toms shown in this table, statistically significant ORs
were identified for a given gEUD or D cutoffs in every
case (Table 4). More specifically, for the symptom of ur-
gency, the biological doses range between 59.7–61.6 for
corresponding statistically significant ORs of 7.4–11.4.
For frequency, the biological doses range between 55.9–
57.7 for ORs of 4.4–9.4. For nocturia, the biological
doses range between 40.9–52.5 for ORs of 4.5–6.6. For
the symptom of incontinence, no statistically significant
dose cutoffs and OR were found. The NTCP predictions
against the actual response rates were in agreement (dif-
ferences ranged between 0.0–0.1%) for all the models
and symptoms. Regarding the correlation of the NTCP
prediction against the actual outcome data, the symptom
of urgency shows slightly higher AUC values (0.66), but
worse AIC values (108.6–109.9). On the other hand, the
symptom of frequency shows the best combination of
AUC and AIC values (0.63–0.64 and 78.6–79.0, respect-
ively) (Table 3).
Discussion
It is well-known that radiation therapy causes an impact
on QOL and specifically patient-reported urinary issues.
Many patients after radical prostatectomy require radi-
ation treatment to the prostate bed; these patients are
especially vulnerable to urinary symptoms during radi-
ation treatment due to the prior surgery. However, the
association between doses received to the bladder and
development of patient-reported acute urinary issues in
this specific patient population has not been well-
studied. To our knowledge, this is the first study to ad-
dress this important knowledge gap.
Many of these studies use physician-reported toxicity,
but patient-reported outcomes (PRO) have become an
increasingly important way to measure quality of life
(QOL) after cancer treatment [6–10]. Reports indicate
that PRO-QOL data are often not in-line with physician-
reported acute toxicity for prostate cancer patients [13,
27–32]. Additionally, the acute toxicity of post-
prostatectomy radiation and dosimetric correlations
continues to be understudied. Although, there are many
studies investigating frequency and severity issues of
acute toxicity after prostate cancer radiotherapy, they
are mostly based on physician-reported measures of
quality-of-life [13, 27–38]. Additionally, not all patients
treated in these studies were treated using modern treat-
ment techniques. All the patients included in this study
were treated with IMRT receiving a median dose of
66.6 Gy. They also underwent regular image guidance.
This represents modern-era treatment techniques for
this cohort, and should therefore provide an accurate
picture of acute GU toxicity in current practice.
The model parameters based on the LENT/SOMA
scoring system (≥ Grade 2) were D50 = 69.56 Gy, γ = 1.7
and s = 0.35 for the RS model and D50 = 78.68 Gy, m =
0.17 and n = 0.09 for the LKB model [39, 40]. Regarding
the symptoms of bladder contracture and volume loss, the
parameters of the RS model are D50 = 80.0 Gy, γ = 3.0
and s = 0.18, whereas those of the LKB model are
D50 = 80.0 Gy, m = 0.11 and n = 0.5 [41–43]. All the
aforementioned parameters were derived using physician-
Table 1 Dosimetric parameters in the patients with and
without toxicity
No Toxicity
(mean ± standard deviation)
Toxicity
(mean ± standard deviation)
Frequency
Patients 71 14
Dmean (Gy) 50.0 ± 11.5 47.6 ± 9.5
V18 (cc) 99.2 ± 43.3 133.4 ± 63.1
Nocturia
Patients 71 15
Dmean (Gy) 49.4 ± 11.0 48.2 ± 14.4
V40 (cc) 76.7 ± 32.2 97.0 ± 48.2
Urinary urgency
Patients 64 26
Dmean (Gy) 47.4 ± 11.1 53.3 ± 11.2
V18 (%) 84.2 ± 18.5 91.8 ± 15.6
Incontinence
Patients 74 13
Dmean (Gy) 48.6 ± 11.9 52.4 ± 9.4
V40 (%) 68.0 ± 21.8 75.8 ± 17.8
The presented dose volume values (V18 and V40) are those that showed the
highest area under the receiver operating characteristic curve (AUC) values in
each case
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rated outcome scores. The last few years, there is a trend
to evaluate radiation-induced toxicity using patient-
reported outcome scores. For the symptom of urgency,
the parameters for the LKB model are D50 = 150.0,
m = 0.37 and n = 0.01 [44]. The values that were de-
rived by the present study using a different outcome
scoring system for the symptom of urgency during
the period of RT indicate a higher radiosensitivity
(lower D50). Regarding acute urinary symptoms, it
has been recently reported that an impact of dosimetric
parameters was found for most symptoms (frequency,
intermittency, urgency and nocturia), confirming the
Table 2 Summary of the best estimates and 95% confidence intervals of the parameters of the three examined normal tissue
complication probability models for four acute bladder symptoms, respectively
Lyman-Kutcher-Burman (LKB) model
Symptom Vref D50 (Gy) m n
Urinary urgency Whole 64.2 (54.6–78.7) 0.50 (0.35–0.88) 1.00 (0.40–7.00)
Urinary incontinence Whole 95.0 (77.2–130.6) 0.45 (0.35–0.62) 0.50 (0.13–3.51)
Frequency 150cm3 83.1 (61.3–132.9) 0.56 (0.43–0.81) 1.00 (0.55–7.00)
Nocturia 150cm3 85.4 (63.0–143.1) 0.60 (0.47–0.87) 1.00 (0.40–7.00)
Logit model
Symptom Vref D50 (Gy) k n
Urinary urgency Whole 67.6 (60.0–77.7) 3.04 (1.67–4.63) 0.49 (0.20–3.44)
Urinary incontinence Whole 96.7 (85.8–107.6) 4.55 (3.19–5.92) 0.01 (0.01–0.07)
Frequency 150cm3 117.2 (82.0–183.1) 1.35 (0.95–1.86) 1.00 (0.40–7.00)
Nocturia 150cm3 123.1 (81.6–197.0) 1.23 (0.86–1.69) 1.00 (0.40–7.00)
Relative Seriality model
Symptom Vref D50 (Gy) γ s
Urinary urgency Whole 68.5 (55.6–86.4) 0.51 (0.28–0.74) 10−4 (10−5-7 × 10−4)
Urinary incontinence Whole 103.1 (83.8–138.0) 0.59 (0.41–0.81) 0.85 (0.08–5.92)
Frequency 150cm3 134.7 (84.2–336.7) 0.33 (0.18–0.48) 0.82 (0.33–5.73)
Nocturia 150cm3 119.5 (74.7–280.9) 0.34 (0.18–0.49) 0.73 (0.29–5.12)
Responders are considered the patients with ≥2 levels of increase from baseline in the patient reported toxicity scale
Fig. 2 The dose-response curves of bladder, for the acute symptoms of urinary urgency, urinary incontinence, frequency and nocturia for the
three models. The unit on the dose axis is either the biologically effective uniform dose (D or BEUD), in the cases of the Relative Seriality (RS)
model or the generalized equivalent uniform dose (gEUD) in the cases of the Lyman-Kutcher-Burman (LKB) and Logit models. The clinical
response rates for different dose intervals (indicated by the horizontal error bars) are also plotted
Mavroidis et al. Radiation Oncology  (2018) 13:17 Page 5 of 8
existence of a dose–volume/surface effect for acute effects
[45]. However, those data and similar ones from other
studies have not been modelled yet. So, in the literature
there is lack of model parameter values for acute urinary
symptoms based on PRO-QOL scoring protocols.
As indicated by the results of the goodness-of-fit, the
three models studied here fitted the clinical data with
similar accuracy. However, it should be pointed out that
an agreement between those models is observed when
fitting organs showing a parallel behavior, whereas dis-
crepancies between them are observed when fitting or-
gans of serial behavior. In the literature, we could not
identify any other study deriving parameters for multiple
NTCP models for acute urinary symptoms. In order to
clinically validate the derived parameters, an independ-
ent cohort of patients with similar clinical characteristics
should be available. In this study, the correlation of
those parameters with the outcome data was mainly per-
formed to identify the differences between the models
regarding the goodness-of-fit process.
It should be noticed that for the symptoms of urgency
and incontinence, the dose/volume metrics that corre-
lated with the outcome data and the NTCP models had
the volume expressed in percentage of the whole of vol-
ume of bladder, whereas frequency and nocturia had the
best correlation when the volume was expressed in abso-
lute units (cc). This means that for the symptoms of fre-
quency and nocturia it is not the relative size of bladder
receiving a given dose that is associated with them but
the absolute volume of bladder. It is also clinically rele-
vant that we did not find a clear association between
bladder dose and urinary flow or dysuria. This is consist-
ent with our clinical hypotheses. Radiation therapy can
cause slower urinary flow due to swelling of the prostate
which obstructs the urethra; but in patients who have
previously undergone a radical prostatectomy, this
mechanism does not apply. Further, clinically, dysuria is
commonly deemed to be related to radiation irritation of
the urethra, which was not assessed in this study be-
cause a Foley catheter is not routinely used in our treat-
ment planning process. Therefore, the null findings in
our analysis related to urine flow and dysuria provide
further face validity regarding the results.
The current study does not account for other clinical
factors that may have been associated with acute urinary
toxicity, such as the use of medications (hormonal ther-
apy), Prostate-specific antigen (PSA), Gleason score and
volume of the gross tumor volume (GTV). However, few
of these factors have consistently been found to impact
acute toxicity [1, 46]. Most of those factors are not directly
related to the function of bladder but mostly affect the
treatment plan and consequently the dose distribution de-
livered to the patient. So, analyzing the dose to bladder
against those symptoms should lead to better correlations.
Table 4 Summary of the cutoff values of gEUD / D, which
result in a statistically significant Odds Ratio (OR) larger than 1
for the different acute urinary symptoms
Parameters Odds ratio
gEUD / D OR (95%CI)
Lyman-Kutcher-Burman (LKB) model
Urinary urgency 60.2 9.3 (1.7–49.8)
Urinary incontinence 60.6 3.4 (0.7–15.8)
Frequency 55.9 9.4 (1.4–62.9)
Nocturia 52.3 6.6 (1.6–27.0)
Logit model
Urinary urgency 61.6 7.4 (1.3–40.9)
Urinary incontinence 64.9 4.1 (0.5–34.0)
Frequency 56.2 9.4 (1.4–62.9)
Nocturia 52.5 6.6 (1.6–27.0)
Relative Seriality model
Urinary urgency 59.7 11.4 (2.2–59.7)
Urinary incontinence 60.5 3.4 (0.7–15.8)
Frequency 57.7 4.4 (1.2–16.3)
Nocturia 40.9 4.5 (1.4–14.6)
CI confidence interval
gEUD generalized Equivalent Uniform Dose
D biologically effective uniform dose
Table 3 Summary of the results from the fit of the four normal
tissue complication probability models for the different acute
urinary symptoms during radiotherapy, respectively
Parameters AUC LLmax Pworse-fit (%) AIC
Lyman-Kutcher-Burman (LKB) model
Urinary urgency 0.66 −51.2 60.2 108.6
Urinary incontinence 0.58 −36.0 60.1 78.3
Frequency 0.64 −36.2 60.1 78.6
Nocturia 0.64 −38.2 60.1 82.7
Logit model
Urinary urgency 0.66 −51.8 60.1 109.9
Urinary incontinence 0.55 −36.6 60.1 79.5
Frequency 0.64 −36.3 60.1 78.9
Nocturia 0.64 −38.2 60.1 82.8
Relative Seriality model
Urinary urgency 0.66 −51.4 60.4 109.2
Urinary incontinence 0.57 −36.0 60.1 78.2
Frequency 0.63 −36.3 60.1 79.0
Nocturia 0.67 −37.7 60.1 81.7
AUC area under the receiver operating characteristic curve
LLmax maximum of the log-likelihood function
Pworse-fit probability of achieving a worse fit compared to the fitted
parameter values
AIC Akaike information criterion
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Moreover, given the small sample size of this study add-
itional subset analyses could not performed.
A few points of caution should be mentioned regard-
ing this study. First, it is difficult to compare the results
of this study with previously reported findings due to
the fact that a new patient reported outcome system
(PCSI) was used for the acute urinary symptoms instead
of the most common CTCAE scoring system. Second,
although patient toxicity was based on the validated
QOL instrument specifications, the definition of a sig-
nificant toxicity was somewhat subjective (a two-point
increase in the symptom score on the four-point symp-
tom scale). However, other groups using patient reported
outcomes have followed this approach because it ac-
knowledges the importance of taking into account the
baseline status [47–49]. Third, we had limited possibility
of performing sub-sample test validation or k-fold valid-
ation of our models due to the size of our dataset. A fu-
ture goal should be to collect new clinical data to
separately validate the predictive ability of the models
and their suitability to be used as constraints in treat-
ment planning.
Conclusions
In this study it was shown that all the examined NTCP
models (LKB, Logit and Relative Seriality) could fit the
individual patient reported outcome data with very simi-
lar accuracy. The NTCP predictions of frequency corre-
lated a little better with the outcome data than the rest
of the acute symptoms. The values of the model parame-
ters for the different acute symptoms could not be com-
pared with previously published values, which is most
likely attributed to the patient reported outcome system
used instead of the CTCAE system. Further investigation
with a larger patient cohort could verify the suitability of
using the values of the NTCP model as an additional
constraint in IMRT treatment plan optimization.
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